Day: March 12, 2024
Tonix recently reported results from second positive Phase 3 trial of Tonmya™ for the management of fibromyalgia
In the U.S., New Drug Application (NDA) submission to the FDA planned for the second half of 2024
In Japan, China and most countries in Europe cyclobenzaprine is a New Chemical Entity
CHATHAM, N.J., March 12, 2024 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals, will present at the 2024 BIO-Europe Spring Convention being held March 18-20, 2024 in Barcelona, Spain. The presentation will take place on Tuesday, March 19, 2024 at 10:45 a.m. CET in Room 133/134 of the CCIB Barcelona.
To schedule...
electroCore to Participate in Upcoming Investor Conferences
Written by Customer Service on . Posted in Public Companies.
ROCKAWAY, N.J., March 12, 2024 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that the Company’s Chief Strategy Officer, Joshua Lev, is scheduled to attend the 36th Annual Roth Conference taking place at The Ritz Carlton Laguna Niguel in Dana Point, California on March 17 – 19, 2024. electroCore will host 1×1 investor meetings on March 18 and 19, 2024. Please contact Roth MKM to schedule a 1×1 meeting.
In addition, Dan Goldberger, CEO of electroCore, Inc. is scheduled to participate in the 23rd Annual Needham Virtual Healthcare Conference on April 8 – 11, 2024. Mr. Goldberger will give a company presentation on April 8th at 3:00 pm and will host 1×1 investor meetings throughout the conference. Please contact Needham to schedule...
SS Innovations’ SSi Mantra Surgical Robotic System used to perform Mitral Valve Replacement
Written by Customer Service on . Posted in Public Companies.
The first Mitral Valve Replacement using the Made in India SSi Mantra Surgical Robotic System was successfully performed at the Narayana Institute of Cardiac Sciences in Bengaluru, India
FORT LAUDERDALE, Fla., March 12, 2024 (GLOBE NEWSWIRE) — SS Innovations International, Inc. (the “Company” or “SS Innovations”) (OTC: SSII), a developer of innovative surgical robotic technologies dedicated to making world class robotic surgery affordable and accessible to a global population, today announced that surgeons have successfully performed the world’s first mitral valve replacement using the Made in India, SSi Mantra Surgical Robotic System. This procedure was carried out at the Narayana Hrudayalaya Institute of Cardiac Sciences in Bengaluru, India, and represents a milestone in the treatment of heart disease using the SSi Mantra Surgical...
Galectin Therapeutics Expands Clinical Team with the Appointment of Khurram Jamil, M.D. as Vice President, Clinical Development
Written by Customer Service on . Posted in Public Companies.
NORCROSS, Ga., March 12, 2024 (GLOBE NEWSWIRE) — Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced the appointment of Khurram Jamil, M.D. as Vice President, Clinical Development. Dr. Jamil brings to Galectin almost two decades of experience in clinical development across the biotechnology industry.
“We are pleased to welcome Khurram to the Galectin team at such a meaningful time of our development program” said Pol F. Boudes, M.D., Chief Medical Officer. “His breadth of expertise in clinical development, especially in hepatology and liver cirrhosis, along with his experience with regulatory interactions and successful New Drug Registration, will be critical as the adaptive Phase 2b/3 NAVIGATE trial of belapectin in patients with NASH cirrhosis progresses...
Abacus Life to Announce Fourth Quarter 2023 Financial Results on Thursday, March 21, 2024
Written by Customer Service on . Posted in Public Companies.
ORLANDO, Fla., March 12, 2024 (GLOBE NEWSWIRE) — Abacus Life, Inc. (“Abacus” or the “Company”) (NASDAQ: ABL), a leading buyer of life insurance policies and vertically integrated alternative asset manager specializing in specialty insurance products, today announced it will release its Fourth Quarter 2023 financial results after the market closes on Thursday, March 21, 2024.
Abacus will hold a conference call to discuss the financial results at 5:00 pm Eastern Time on March 21, 2024. A live webcast of the conference call will be available on Abacus’ investor relations website at ir.abacuslife.com. The dial-in number for the conference call is (877) 407-9716 (toll-free) or (201) 493-6779 (international). Please dial the number 10 minutes prior to the scheduled start time.
A webcast replay of the call will be available at ir.abacuslife.com...
X4 Pharmaceuticals to Report Fourth-Quarter and Full Year 2023 Financial Results and Host a Conference Call and Webcast on March 21, 2024
Written by Customer Service on . Posted in Public Companies.
BOSTON, March 12, 2024 (GLOBE NEWSWIRE) — X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that it will be reporting financial results for the fourth-quarter and full year ended December 31, 2023 and providing corporate updates on Thursday, March 21, 2024.
The company will host a conference call and webcast on the same day at 8:30 a.m. ET. The conference call can be accessed by dialing 1-877-451-6152 from the United States or 1-201-389-0879 internationally, followed by the conference ID: 13744107. The live webcast will be accessible through the investor relations section of X4 Pharmaceuticals’ website at www.x4pharma.com. Following the completion of the call, a webcast replay will be available on the website.
About X4 Pharmaceuticals...
Spectral AI Announces New US Government Contract to Further Accelerate the Development of the Handheld Version of DeepView™ Wound Imaging System
Written by Customer Service on . Posted in Public Companies.
In the past six months, the Company has announced over $149 million of non-dilutive financing from the US Government for the DeepView™ Wound Imaging System
DALLAS, March 12, 2024 (GLOBE NEWSWIRE) — Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced a new contract with the Defense Health Agency (DHA) and the US Army Medical Material Development Activity (USAMMDA) that provides significant additional support for the development of the handheld version of DeepView™ Wound Imaging System called DeepView SnapShot® M.
This newly secured contract is valued at over $500,000 and will build on the previous awards from other U.S. Government Agencies focused on advancing...
Provectus Biopharmaceuticals Announces Notices of Allowance and Award for U.S. Patents of Rose Bengal Sodium in Virology, Pediatric Solid Tumor Cancers, and Vaccines
Written by Customer Service on . Posted in Public Companies.
KNOXVILLE, TN, March 12, 2024 (GLOBE NEWSWIRE) — Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced that the United States Patent and Trademark Office (“USPTO”) has allowed patent application 17/212,723, titled “Novel Uses of Halogenated Xanthenes in Oncology and Virology.” The application covers the use of Provectus’s pharmaceutical-grade rose bengal sodium (“RBS”) drug substance for the treatment of infectious diseases, such as coronaviruses.
The USPTO has also allowed patent application 17/344,418, titled “In Vitro and Xenograft Anti-Tumor Activity of a Halogenated-Xanthene Against Refractory Pediatric Solid Tumors.” This prospective award covers the use of RBS in combination with one or more immune checkpoint inhibitors and is a continuation of U.S. patent 11,058,664 (2021), Provectus’s...
NewAmsterdam Pharma Doses First Patient in Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib and Ezetimibe in Patients with HeFH and/or ASCVD
Written by Customer Service on . Posted in Public Companies.
— TANDEM is designed to evaluate obicetrapib and ezetimibe fixed-dose combination (“FDC”) as an adjunct to diet and maximally tolerated lipid lowering therapy in patients with HeFH, ASCVD or ASCVD risk equivalents requiring additional lowering of low-density lipoprotein cholesterol (“LDL-C”) —
— Company expects to report topline data in the first quarter of 2025 —
— TANDEM is being conducted in parallel with BROOKLYN, BROADWAY and PREVAIL pivotal Phase 3 studies; data from BROOKLYN and BROADWAY expected in 3Q and 4Q 2024, respectively —
NAARDEN, The Netherlands and MIAMI, March 12, 2024 (GLOBE NEWSWIRE) — NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk...
Bright Mountain Media’s MomLife Panel Empowers Brands with Insights Directly from the Parenting Front Lines
Written by Customer Service on . Posted in Public Companies.
Moms Have an Incredible Spending Power of $2 Trillion and Influence Over 85% of Household Purchasing Decisions. With the MomLife panel, brands can access moms across the US.
Boca Raton, FL, March 12, 2024 (GLOBE NEWSWIRE) — Bright Mountain Media, Inc. (OTCQB: BMTM) (“Bright Mountain” or the “Company”), a global holding company focused on digital publishing, advertising technology, consumer insights, and creative and media services, today announced the continued growth of its MomLife Panel, a community of diverse and engaged moms eager to share their experiences and perspectives.
Launched in September 2023, MomLife combines the expertise of Big Village Insights in delivering comprehensive customer insights with Wild Sky Media’s editorial authority in the realm of Moms and Motherhood. By leveraging cutting-edge technology...